Literature DB >> 2901665

The potency and kinetics of the beta-adrenergic receptors on human neutrophils.

H Mueller1, H J Motulsky, L A Sklar.   

Abstract

The binding to catecholamines to the beta-adrenergic receptors on human polymorphonuclear leukocytes rapidly inhibits cell responses stimulated by chemoattractant ligands. As a first step in understanding the mechanism of the inhibition, we investigated the number of beta-receptors required to optimally block superoxide anion production, a response that is measured kinetically by a convenient spectrophotometric assay for the reduction of cytochrome c. We found that after blockade of 50-60% of the beta-adrenergic receptors with an irreversible antagonist, maximal inhibition of the response was still elicited by isoproterenol (ISO). Next we investigated the kinetics with which superoxide generation is inhibited. We found that half-maximal inhibition was observed at 3 x 10(-8) M ISO, which approximates the Kd because many of the receptors are involved. Cell responsiveness recovered when propranolol was added between the time of ISO and chemoattractant addition. From the recovery we estimated that the half-time for ISO dissociation is less than 10 sec. Finally, we examined the rate at which cell responses decay following ISO administration after chemoattractant. Optimal rates of inhibition, turning off oxidant production in seconds, occur at ISO concentrations greater than or equal to 3 x 10(-7) M. Taken together, these observations are consistent with an association rate constant for ISO estimated to be greater than or equal to 10(8) M-1min-1 and a dissociation rate constant greater than or equal to 4 min-1. These results are discussed in terms of the available data concerning the binding of agonists to beta-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901665

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Evaluation of rat neutrophil beta-adrenergic receptors by microphysiometry.

Authors:  T P LaBranche; L B Gray; P Eyre
Journal:  Vet Res Commun       Date:  2001-02       Impact factor: 2.459

2.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists.

Authors:  David A Sykes; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Beta-adrenergic modulation of FMLP- and zymosan-induced intracellular and extracellular oxidant production by polymorphonuclear leukocytes.

Authors:  S Kopprasch; A Gatzweiler; J Graessler; H E Schröder
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

4.  Guanine nucleotide binding properties of rap1 purified from human neutrophils.

Authors:  G M Bokoch; L A Quilliam
Journal:  Biochem J       Date:  1990-04-15       Impact factor: 3.857

Review 5.  Biology of the Rap proteins, members of the ras superfamily of GTP-binding proteins.

Authors:  G M Bokoch
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

6.  Beta-adrenoceptor control of immune function in congestive heart failure.

Authors:  A S Maisel; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

7.  Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity.

Authors:  Irena Brunskole Hummel; Michael T Reinartz; Solveig Kälble; Heike Burhenne; Frank Schwede; Armin Buschauer; Roland Seifert
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Quantitative modeling of GRK-mediated beta2AR regulation.

Authors:  Sharat J Vayttaden; Jacqueline Friedman; Tuan M Tran; Thomas C Rich; Carmen W Dessauer; Richard B Clark
Journal:  PLoS Comput Biol       Date:  2010-01-22       Impact factor: 4.475

9.  Leukocyte Subset Changes in Response to a 164-km Road Cycle Ride in a Hot Environment.

Authors:  Hui-Ying Luk; Amy L McKenzie; Anthony A Duplanty; Ronald G Budnar; Danielle Levitt; Alex Fernandez; Elaine C Lee; Lawrence E Armstrong; Jakob L Vingren
Journal:  Int J Exerc Sci       Date:  2016-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.